Matthew L. Kaplan

Director at Nuvectis Pharma · 2 reported transactions in 1 company · latest trade Nov 5, 2025

Their record

Across their whole record, 1 purchase can be measured; 1 did better than the S&P 500 over the next 6 months.

Typical move +51.5%, S&P 500 +6.1% over the same days.


Nuvectis PharmaNVCT	Bought $64.2K · 11,000 shares	Nov 5, 2025	S&P 500 +14.0%thru Oct 28

Nov 5, 2025 · NVCT

$64.2K

S&P 500 +14.0%thru Oct 28

2 transactionsPro adds every trade with how it did, their holdings and the money-flow chartPro is $29 a month

Built from their public trade reports and market prices: past moves, not predictions or advice.